Recent News

• 11.05.2026 - Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
• 10.06.2026 - Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
• 09.10.2026 - Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
• 08.14.2026 - Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
• 08.04.2026 - Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
• 06.23.2026 - Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
• 03.31.2026 - Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
• 03.17.2026 - Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
• 02.26.2026 - Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
• 12.19.2025 - Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

Recent Filings

• 10.13.2026 - ARS Annual Report to Security Holders
• 10.13.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 10.13.2026 - DEF 14A Other definitive proxy statements
• 10.02.2026 - PRE 14A Other preliminary proxy statements
• 08.14.2026 - 8-K Current report
• 08.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2026 - EX-99.1 EX-99.1
• 08.04.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.04.2026 - 8-K Current report